Objective To determine the ability of the Internet-based Spaeth/Richman Contrast Sensitivity (SPARCS) in assessing the change in contrast sensitivity (both central and peripheral) post-treatment... Show moreObjective To determine the ability of the Internet-based Spaeth/Richman Contrast Sensitivity (SPARCS) in assessing the change in contrast sensitivity (both central and peripheral) post-treatment with travoprost 0.004%. Design This is a prospective observational study. Methods and participants. Data of 62 eyes (33 patients) undergoing treatment for naive POAG patients were analysed. Patients were followed up for a period of six months after starting topical travoprost (Travatan 0.004%, Alcon), and the change in central and peripheral CS was studied. Results Mean total SPARCS score at baseline was 69 +/- 10.99, improved to 74.62 +/- 9.50 after 6 months of therapy (p: 0.001) in all the glaucoma severity groups. Mean SPARCS score at baseline in mild glaucoma group was 72.05 +/- 9.87, in the moderate glaucoma group, it was 62.23 +/- 9.2, and in the severe glaucoma group, it was 59.36 +/- 11.65. After 6 months of treatment with travoprost, the CS improved to 76.05 +/- 8.36 in mild group, 76.69 +/- 8.82 in moderate group and 67.18 +/- 11.15 in severe group (p value: 0.014). The percentage change in the CS from baseline showed significant improvement in the superotemporal quadrant at 1 month (p value: 0.032), superonasal quadrant (p value: 0.049), inferotemporal quadrant at 3 months (p value: 0.003) and 6 months (p value: 0.039). Inferonasal quadrant was affected most by glaucoma. A statistically significant correlation was seen between total SPARCS score with MD and PSD. Correlation was also seen between the percentage change in CS and average RNFL thickness at 3 and 6 months. Conclusion Both central and peripheral CS improve following IOP reduction with travoprost. Change in the CS has a significant correlation with RNFL thickness and the perimetric indices. Show less
